Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Post by goldmikeon Dec 21, 2020 11:37am
204 Views
Post# 32152788

MindMed MMED vs BetterLife BETR

MindMed MMED vs BetterLife BETR

MindMed is one trick Pony get BetterLife BETR today's transcend acquisition news is phenomenal This was $28 two years ago. Load up get ready for epic run.. In addition to psychedelics look up interferon treatment huge in UK 

BETR stock might hit $10 and here is why  just Look up Synairgen (SNG.L) gained by 456% in a single day on news of positive results from its clinical trial of SNG001, an inhaled formulation of interferon beta, in hospitalised COVID-19 patientsBETR has its own COVID-19 therapeutic called AP-003, an inhaled formulation of interferon alpha 2b (IFNa2b)BETR's AP-003 inhalation applies INFa2b directly to the lungswhich may enable infected cells to halt viral replicationAP-003 inhalation may help to restore the initial immune response to COVID-19. Reports over the weekend of a new more contagious strain of COVID-19will create renewed interest in COVID-19 therapeutics.
$400M competitor.. news today 

https://finance.yahoo.com/news/betterlife-closes-acquisition-second-generation-070000008.html?.tsrc=applewf

 

<< Previous
Bullboard Posts
Next >>